PV Bulletin

Health Canada Guidance on Clinical Trials Involving Human Subjects (GUI-0100)

Health Canada published Version 4 of GUI-0100, providing updated guidance on compliance with Division 5 of the Food and Drug Regulations for clinical trials involving human subjects.

Primary source: Good clinical practices: Guidance documents - Canada.ca

PV Impact Brief

Urgency: HighConfidence: high

What changed

The guidance document specifies new timelines for SUADR reporting, requiring notification within 7 days for serious unexpected adverse reactions that occur during clinical trials, and within 15 days for events occurring outside Canada.

Why it matters

Compliance with these revised reporting requirements is crucial for maintaining safety standards in clinical trials and ensuring that sponsors effectively monitor and report safety data to Health Canada and investigators.

Action needed

Clinical safety and pharmacovigilance teams must ensure that their SUADR reporting processes are aligned with the new 7-day and 15-day notification timelines, and maintain robust systems for collecting safety data from international sites.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
ICSRCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review before 2026-08-14.

Policy change details

Document type
Guidance Document
Policy status
revised
Publication date
2026-08-14
Effective date
2026-08-14
Policy change
Health Canada published Version 4 of GUI-0100, providing updated guidance on complying with Division 5 of the Food and Drug Regulations for clinical trials involving human subjects. The update aligns with the full adoption of ICH E6(R3) Good Clinical Practice guidelines and covers risk-based approaches, data governance, and sponsor responsibilities for safety monitoring.

Key changes

Updates to Serious unexpected adverse drug reaction (SUADR) reporting requirements (Section 6), adoption of ICH E6(R3) principles, and clarification of sponsor obligations for expedited reporting of safety events occurring both inside and outside Canada.

Affected workflows

ICSRCountry Compliance

Responsible groups

Clinical SafetyPharmacovigilance OperationsClinical Trial Sponsors

PV impact

Clinical safety and PV teams must ensure that their SUADR reporting processes are aligned with the clarified 7-day and 15-day timelines for expedited notification. Sponsors must maintain robust systems for capturing safety data from international trial sites and ensuring consistent reporting to Health Canada and investigators.

View regulator source

Source document details

Exact policy details

Regulatory Authority
Food and Drug Regulations, Part C, Division 5
Applies to: This guidance document applies to parties involved in clinical trials of drugs in human participants in Canada.
Source Document Overview · p. 1 · High · Source
Effective Date
August 14, 2026
Applies to: Date when the guidance document was published and implemented.
Source Document Overview · p. 1 · High · Source
ICH E6(R3) Full Adoption Date
April 1, 2026
Applies to: Date when ICH guidance E6(R3) Good Clinical Practice was fully adopted by Health Canada.
Introduction - Source Document · p. 6 · High · Source
Clinical Trials Exclusions
This document does not apply to clinical trials studying medical devices, natural health products (NHPs), or observational studies.
Applies to: Specific exclusions outlined for the scope of the guidance document.
Scope - Source Document · p. 5 · High · Source
Authorization Requirement for Clinical Trials
No person can sell or import a drug for clinical trials involving humans unless authorized.
Applies to: Requirement for the authorizations under subsection C.05.006.
C.05.002 - Application · p. 8 · High · Source

Workflow rule impacts

Country ComplianceClinical Trial Sponsors

Requirement to comply with updated ICH E6 standards.

Implementation of new regulations and guidelines for clinical trials.

Guidance for implementation section provides detailed compliance requirements. · p. 7 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Aug 14, 2026

Full briefing

Practical implication

Clinical safety and pharmacovigilance teams must ensure that their SUADR reporting processes are aligned with the new 7-day and 15-day notification timelines, and maintain robust systems for collecting safety data from international sites.

The updated GUI-0100 aligns with ICH E6(R3) Good Clinical Practice guidelines and specifies new reporting requirements for Serious Unexpected Adverse Drug Reactions (SUADRs). Clinical safety and pharmacovigilance teams must adhere to clarified reporting timelines of 7 days for certain events and 15 days for others, applying to safety events occurring both within and outside Canada.

What changed: The guidance document specifies new timelines for SUADR reporting, requiring notification within 7 days for serious unexpected adverse reactions that occur during clinical trials, and within 15 days for events occurring outside Canada.

Why it matters: Compliance with these revised reporting requirements is crucial for maintaining safety standards in clinical trials and ensuring that sponsors effectively monitor and report safety data to Health Canada and investigators.

Practical implication: Clinical safety and pharmacovigilance teams must ensure that their SUADR reporting processes are aligned with the new 7-day and 15-day notification timelines, and maintain robust systems for collecting safety data from international sites.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Health Canada#Safety Signals#Reporting Requirement#revised#policy-change#firecrawl-policy-agent#Guidance Document

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward